89123-58-0

Basic information

• Product Name: 5-BROMO-PYRAZINE-2,3-DIAMINE
• Synonyms: 5-BROMO-2,3-DIAMINOPYRAZINE;5-BROMO-PYRAZINE-2,3-DIAMINE;2,3-DIAMINO-5-BROMOPYRAZINE, 97%;Pyrazine, 2,3-diamino-5-bromo-
• CAS NO: 89123-58-0
• Molecular Formula: C₄H₅BrN₄
• Molecular Weight: 189.01
• Mol File: 89123-58-0.mol
• Article Data: 8

Chemical Properties

• Melting Point: 212-216 °C (dec.)
• Boiling Point: 357.1 °C at 760 mmHg
• Flash Point: 169.8 °C
• Appearance: /
• Density: 1.956g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.731
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 2.72±0.10(Predicted)
• CAS DataBase Reference: 5-BROMO-PYRAZINE-2,3-DIAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-PYRAZINE-2,3-DIAMINE(89123-58-0)
• EPA Substance Registry System: 5-BROMO-PYRAZINE-2,3-DIAMINE(89123-58-0)

Safety Data

• Hazard Codes: Xn
• Statements: 22-36/37/38-43
• Safety Statements: 26-36/37
• WGK Germany: 3
• Hazardous Substances Data: 89123-58-0(Hazardous Substances Data)

Usage

Uses

2,3-Diamino-5-bromopyrazine

InChI:InChI=1/C4H5BrN4/c5-2-1-8-3(6)4(7)9-2/h1H,(H2,6,8)(H2,7,9)

Upstream product

• 24241-18-7 2-amino-3,5-dibromopyrazine 

Downstream Products

• 56328-71-3 2-bromo-6,7-dimethylpyrazino<2,3-b>pyrazine 
• 91225-51-3 2-bromo-6-methylpyrazino<2,3-b>pyrazine 
• 13134-31-1 pyrazine-2,3-diamine 
• 91225-41-1 5-bromo-1H-imidazo<4,5-b>pyrazine 
• 1361570-47-9 5-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrazine-2,3-diamine 
• 1332875-37-2 5-tert-butyl-4-chloro-2-methyl-2H-pyrazole-3-carboxylic acid (3-amino-5-bromo-pyrazin-2-yl)-amide 
• 882856-62-4 2-bromopyrazino[2,3-b]pyrazine 
• 91225-50-2 2-ethoxy-6,7-diphenylpyrazino<2,3-b>pyrazine 
• 91225-42-2 5-bromo-2-methyl-1H-imidazo<4,5-b>pyrazine 

Relevant articles and documents

New imidazo[1,2-a]pyrazine derivatives with bronchodilatory and cyclic nucleotide phosphodiesterase inhibitory activities

New imidazo[1,2-a]pyrazine derivatives have been synthesized either by direct cyclization from pyrazines or by electrophilic substitutions. The presence of electron donating groups on position 8 greatly enhances the reactivity of the heterocycle towards such reactions on position 3 of the heterocycle. The activities of these derivatives in trachealis muscle relaxation and in inhibiting cyclic nucleotide phosphodiesterase (PDE) isoenzyme types III and IV have been assessed. All compounds demonstrated significantly higher relaxant potency than theophylline. All the derivatives were moderately potent in inhibiting the type IV isoenzyme of PDE but only those with a cyano group on position 2 were potent in inhibiting the type III isoenzyme. Copyright (C) 1999 Elsevier Science Ltd.

JAK kinase inhibitor, preparation method thereof, and application in the field of medicines

The application relates to a JAK kinase inhibitor, a preparation method thereof, and an application in the field of medicines and belongs to the field of medical chemistry. In the application, a series of novel small-molecular JAK inhibitors are provided and are represented as the general formula (II). The compounds have better effects and higher safety in prevention or treatment on JAK-related adaptation diseases.

Preparation method of imidazo-pyrazine medical intermediate

The invention relates to a preparation method of an imidazo-pyrazine medical intermediate. The preparation method comprises the following steps that (a) 2-amino-3,5-dibromo pyrazine and ammonia waterare added into an autoclave, heating is performed under nitrogen protection to reach 110-150 DEG C, reaction is performed, suction filtration is performed to obtain a filter cake after cooling, and drying is performed to obtain a compound II; (b) the compound II is dissolved in N,N-dimethyl formamide, triethyl orthoformate and formic acid are added dropwise, heating reflux is performed under nitrogen protection, and a compound III is obtained through purification; (c) the compound II, N-methyl pyrrolidone, ammonia water and copper sulfate pentahydrate are added into the autoclave, heating is performed under nitrogen protection to reach 130-170 DEG C, reaction is performed, and a compound IV is obtained through purification; (d) 1,4-dioxane and the compound IV are dissolved in an acetic acid solution, a NaNO2 water solution is dropwise added under the condition of ice-water bath, heating is performed to 40-50 DEG C after adding, reaction is performed to separate out solid, and suction filtration and washing are performed. Therefore, the synthesis steps of a final product can be decreased, and accordingly the yield and purify of the product are improved.